arrow
A

Amanda Gilkes

Cardiff University
H指数:32
被引数:5,116

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Impact of FLT3 ‐ ITD Microclones in AML : An EHA AML ‐Specialized Working Group Study

FLT3-ITD微小克隆在AML中的预后影响:EHA AML专业化工作组研究

2026-11-010
PRE
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial

将奎沙替尼与强化化疗联合应用于新诊断AML的老年患者:英国NCRI AML18试验结果

Blood
IF23.1
2026-06-250
OA
Correction: Kingshott et al. Alteration of Metabolic Conditions Impacts the Regulation of IGF-II/H19 Imprinting Status in Prostate Cancer. Cancers 2021, 13, 825

更正:Kingshott et al. 代谢条件的变化影响前列腺癌中IGF-II/H19印记状态的调控。Cancers 2021, 13, 825

Cancers
IF4.4
2026-01-090
OAAI
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial

CPX-351与柔红霉素、阿糖胞苷联合吉姆单抗奥佐米星在非不良风险AML老年患者中的比较:NCRI AML18试验

Blood
IF23.1
2025-11-180
PRE
Safety and Efficacy of Combining Midostaurin and Gemtuzumab Ozogamicin with Induction Chemotherapy in FLT3 mutated AML.

联合中剂量阿糖胞苷和吉妥单抗奥佐米星与诱导化疗在FLT3突变急性髓系白血病中的安全性和有效性。

2025-10-030
OAAI
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival

急性髓系白血病细胞表达高水平的雄激素受体,但不依赖雄激素信号存活。

Leukemia
IF13.4
2025-09-110
OAAI
A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1mut AML in MRDneg remission after intensive induction

对3项大型多中心试验的合并分析证实,在强化诱导后,NPM1mut AML在MRDneg缓解期具有生存优势。

2025-08-220
OAAI
Induction chemotherapy and molecular MRD influence outcomes in KMT2A rearranged AML

诱导化疗和分子MRD影响KMT2A重排AML的结局

Blood
IF23.1
2025-08-080
PRE
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
2023-08-1114
OAAI
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
LEUKEMIA
IF13.4
2023-08-0920
OAAI
Unified classification and risk-stratification in Acute Myeloid Leukemia

急性髓系白血病的统一分类与风险分层

2022-08-0891
OAAI
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
2022-01-044
OAAI
Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
2021-12-0629
OAAI